Literature DB >> 9295179

Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice.

J Lan1, D H Jiang.   

Abstract

To elucidate the neuroprotective effects of the iron chelator desferrioxamine (DFO) and the antioxidant vitamin E on excessive iron-induced free radical damage, a chronic iron-loaded mice model was established. The relationship between striatal iron content, oxidized to reduced glutathione ratio, hydroxyl radical (.OH) levels and dopamine concentrations were observed in DFO or vitamin E pretreated iron-loaded/1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57BL/6 mice. The results demonstrated that both DFO and vitamin E inhibit the iron accumulation and thus reverses the increase in oxidized glutathione (GSSG), oxidized to reduced glutathione ratios, .OH and lipid peroxidation levels. The striatal dopamine concentration was elevated to normal value. Our data suggested that: (1) iron may induce neuronal damage and thus excessive iron in the brain may contribute to the neuronal loss in PD; (2) iron chelators and antioxidants may serve as potential therapeutic agents in retarding the progression of neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9295179     DOI: 10.1007/BF01277665

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  61 in total

1.  The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease.

Authors:  M B Youdim; D Ben-Shachar; G Eshel; J P Finberg; P Riederer
Journal:  Adv Neurol       Date:  1993

2.  Desferrioxamine: a scavenger of superoxide radicals?

Authors:  J Sinaceur; C Ribière; J Nordmann; R Nordmann
Journal:  Biochem Pharmacol       Date:  1984-05-15       Impact factor: 5.858

3.  DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group.

Authors: 
Journal:  Arch Neurol       Date:  1989-10

4.  Desferrioxamine as a lipid chain-breaking antioxidant in sickle erythrocyte membranes.

Authors:  A Hartley; M Davies; C Rice-Evans
Journal:  FEBS Lett       Date:  1990-05-07       Impact factor: 4.124

5.  Effects of methylprednisolone and the combination of alpha-tocopherol and selenium on arachidonic acid metabolism and lipid peroxidation in traumatized spinal cord tissue.

Authors:  R D Saunders; L L Dugan; P Demediuk; E D Means; L A Horrocks; D K Anderson
Journal:  J Neurochem       Date:  1987-07       Impact factor: 5.372

6.  Experimental liver cirrhosis induced by alcohol and iron.

Authors:  H Tsukamoto; W Horne; S Kamimura; O Niemelä; S Parkkila; S Ylä-Herttuala; G M Brittenham
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

7.  Glutathione and ascorbate during ischemia and postischemic reperfusion in rat brain.

Authors:  A J Cooper; W A Pulsinelli; T E Duffy
Journal:  J Neurochem       Date:  1980-11       Impact factor: 5.372

8.  The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons.

Authors:  D Ben-Shachar; G Eshel; J P Finberg; M B Youdim
Journal:  J Neurochem       Date:  1991-04       Impact factor: 5.372

9.  Intraperitoneal deferoxamine therapy for iron overload in children undergoing CAPD.

Authors:  S P Andreoli; M Cohen
Journal:  Kidney Int       Date:  1989-06       Impact factor: 10.612

10.  Protective effect of the iron chelator deferoxamine on cold-induced brain edema.

Authors:  Y Ikeda; K Ikeda; D M Long
Journal:  J Neurosurg       Date:  1989-08       Impact factor: 5.115

View more
  39 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 2.  Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson's disease.

Authors:  Julie K Andersen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 3.  The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy.

Authors:  Alessandra Gaeta; Robert C Hider
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

4.  The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice.

Authors:  M B H Youdim; E Grünblatt; S Mandel
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

5.  Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.

Authors:  Silvia Mandel; Gila Maor; Moussa B H Youdim
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 6.  Hypoxia inducible factor-1 as a target for neurodegenerative diseases.

Authors:  Z Zhang; J Yan; Y Chang; S ShiDu Yan; H Shi
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

7.  Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

Authors:  Shunit Gal; Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  Neurotox Res       Date:  2009-07-16       Impact factor: 3.911

8.  Abnormal differentiation of dopaminergic neurons in zebrafish trpm7 mutant larvae impairs development of the motor pattern.

Authors:  Amanda R Decker; Matthew S McNeill; Aaron M Lambert; Jeffrey D Overton; Yu-Chia Chen; Ramón A Lorca; Nicolas A Johnson; Susan E Brockerhoff; Durga P Mohapatra; Heather MacArthur; Pertti Panula; Mark A Masino; Loren W Runnels; Robert A Cornell
Journal:  Dev Biol       Date:  2013-11-27       Impact factor: 3.582

Review 9.  Redox imbalance in Parkinson's disease.

Authors:  Shankar J Chinta; Julie K Andersen
Journal:  Biochim Biophys Acta       Date:  2008-03-04

Review 10.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.